Keywords: genentech, soars, cancer, drug, avastin, meets, exceeds

Genentech soars as cancer drug Avastin meets and exceeds expectations

Article | 26 May 2003

Print This

Shares in US biotechnology bellwether Genentech went through the roof in mid-morning trading May 19 after the company unveiled Phase III ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in